Chemistry:Amibegron
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H26ClNO4 |
| Molar mass | 403.90 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.[1][2]
On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.[3]
References
- ↑ "Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders". Neuropsychopharmacology 33 (3): 574–87. February 2008. doi:10.1038/sj.npp.1301424. PMID 17460614.
- ↑ "Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression". Pharmacology, Biochemistry, and Behavior 89 (4): 623–6. June 2008. doi:10.1016/j.pbb.2008.02.020. PMID 18358519.
- ↑ Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009.
 |  |
